Clinical Trial Update: Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating whether low-dose esketamine affects maternal depression at 3 years after childbirth.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perinatal Depression
• Postpartum Depression

Drugs mentioned

• SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

Sponsor: Peking University First Hospital | Conditions: Prenatal Depression, Ketamine | Phase 4 | Status: ACTIVE_NOT_RECRUITING